HR 1530
107th Congress
House
Commerce
Administrative procedure
Antitrust law
Civil actions and liability
Drug approvals
Drug industry
Federal Trade Commission
Fines (Penalties)
Generic drugs
Government Operations and Politics
Government paperwork
Health
Independent regulatory commissions
Injunctions
Law
Marketing
Pharmaceutical research
Research and development
Restrictive trade practices
Science, Technology, Communications
Prescription Drug Competition Act of 2001
Introduced: April 4, 2001
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 11, 2001
Sponsor introductory remarks on measure. (CR S10642-10643)
Apr 25, 2001
Referred to the Subcommittee on Health.
Apr 4, 2001
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2001
Introduced in House
Plain-English summary
Prescription Drug Competition Act of 2001 - Requires brand name drug companies and generic drug applicants to file with the Federal Trade Commission and the Secretary of Health and Human Services specified information regarding any agreement regarding the sale or manufacture of a generic drug which the Secretary has determined is the therapeutic equivalent of the brand name drug or for which the applicant seeks a determination of therapeutic equivalence, if such agreement could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.
What's happening now
Sponsor introductory remarks on measure. (CR S10642-10643)
Committees of jurisdiction
3
Cosponsors
1